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Abstract  
Synthesis and spectroscopic properties of nine water soluble zinc(II) complexes of (E)-N-
(pyridin-2-ylmethylene)arylamine (L
n
) with general formula [Zn(X)2(L
n
)] (X = Cl
-
, Br
-
, I
-
; (1 - 
8)) and [Zn(-N3)(N3)(L
3
)]2 (9)) are reported. The complexes were characterized by elemental 
analysis and their spectroscopic properties were studied using UV-Visible, fluorescence, IR and 
1
H NMR spectroscopies. The solid state structures of zinc(II) complexes 2-4 and 6-9 were 
established by single crystal X-ray crystallography. The majority of the structures are 
mononuclear with tetra-coordinate zinc centres (2-4, 6 and 7), except when L carries an 
additional donor atom capable of coordinating zinc (8), in which case the zinc atom has a 
distorted square pyramidal geometry. The centrosymmetric molecule of [Zn(-N3)(N3)(L
3
)]2 (9) 
is binuclear with the zinc atoms in a trigonal bipyramidal coordination environment. In general, 
the dichlorozinc derivatives 1, 3-5 and 8, exhibited moderately elevated in vitro cytotoxic 
potency towards the human epithelial cervical carcinoma (HeLa) cell lines, with 4 as the best 
performer (IC50 value of 18 μM). Apoptosis-inducing activities, assessed by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, showed that the zinc 
complexes facilitated the interaction with DNA interfering with the binding of several 
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transcription factors to its promoter sites, thus inhibiting gene transcription required for the 
biological activity of cells.  
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†Electronic supplementary information (ESI) available: CCDC reference numbers 953170-
953176. For ESI and crystallographic data in CIF format see DOI: XXXXX 
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Introduction 
Metal complexes of -diimine Schiff bases have found increasing applicability as catalyst 
precursors for olefin polymerization. In this perspective, the pioneering work of Brookhart, 
Bennett and Gibson have shown that tridentate 2,6-bis(arylimino)pyridyl metal (Fe or Co) 
dihalides, upon activation with methylaluminoxane (MAO), led to effective catalysts for the 
conversion of ethylene to high-density polyethylene or to -olifins.1 Apart from possible 
structural disparity of the metal complexes of such tridentate 2,6-bis(arylimino)pyridyl ligands, 
bidentate iminopyridyl based ligands were also investigated with first and second row late 
transition metal (Fe, Co, Ni, Cu, Zn and Pd) halides and some of them have shown exceptional 
catalytic activities.
2-7
 These metal catalyst precursors can be prepared by addition of ligands to 
either anhydrous or hydrated dihalides in a suitable solvent. Complexes can be isolated as 
mononuclear species or, depending on both the metal halides and the degree of substitution of 
the pyridine ring, as centrosymmetric dinuclear molecules.
8-11
 By simple modifications of the 
iminopyridyl architecture, the polymerization and/or oligomerization activities of the metal 
complexes can be tuned. All these merits make this class of complexes advantageous over other 
types of metal catalyst, such as metallocenes or geometry constrained species
12-15
. Consequently, 
synthesis of iminopyridyl based ligands has been a major research target in polymerization 
catalysis and there have been some studies with asymmetrical iminopyridyl based ligands
9,11,16
 
and also with long chain aliphatic substituents at the imino nitrogen atom.
17
 Additionally, 
iminopyridyl ligands are suitable synthons in C-C reductive coupling reactions for the synthesis 
of 1,2-dipyridyl-1,2-diaminoethanes.
18
 Recently, some transition metal (Fe(II), Mn(II), Zn(II), 
Cd(II) or Pd(II)) complexes of unsymmetrical iminopyridyl ligands were found to exhibit 
atropisomerism, π-π  stacking and photoluminescence properties.19,20  
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Zinc is abundant in eukaryotes and plays a variety of physiological roles.
21-23
 In addition, 
Zn(II) complexes are often utilized in many fields such as radioprotection,
24
 antidiabetic insulin-
mimemetism,
25,26 
antibacterial or antimicrobial agents,
27-29 
tumour photosensitizers
30
 and binder 
complexes at DNA sites
31-34
. The development of metal chelators for the attenuation of metal-
involved neurodegeneration in Alzheimer’s disease (AD) and other neurodegenerative diseases 
are matters of current interest.
35-42
 In this perspective, iminopyridyl based zinc(II) complexes 
were found to be involved in targeting and modulating amyloid-β (Aβ) species which could 
serve as suitable chemical tools for investigating metal-Aβ-associated events in AD.41 
Furthermore, the use of Zn(II) species as antitumour drugs is very intriguing with respect to 
existing antitumour therapies;
43
 Zn ions are preferred by hydrolytic enzymes due to its redox 
inertness, low toxicity, hard Lewis acid properties and bioavailability. Hence, efficient Zn(II)-
based hydrolytic cleavage agents are good candidates for biomedical applications.
44,45
  
In view of the conspicuous importance of the unsymmetrical iminopyridyl systems as 
metal chelators in catalysis and in biology, we now report the synthesis and full characterization 
of water soluble zinc(II) compounds of (E)-N-(pyridin-2-ylmethylene)arylamine (L
n
), 
[Zn(X)2(L
n
)] (X = Cl
-
, Br
-
, I
-
) (1- 8) and [Zn(-N3)(N3)(L
3
)]2 (9) (Scheme 1), and  their potential 
role as cytotoxic agents. Indeed, the nitrogen environment of the coordination sphere of the zinc 
compounds coupled with their water solubility are likely to facilitate membrane permeability.
46
 
Consequently, the dichlorozinc compounds 1, 3-5 and 8 were investigated in vitro on HeLa 
tumour cell lines in order to assess the influence of various substituents and of the metal 
coordination number on the biological activities.  
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These compounds were characterized by elemental analysis and molar conductance data 
while their spectroscopic properties were studied using UV-Visible, fluorescence, IR and 
1
H 
NMR spectroscopy. Detailed structural information on mononuclear 1 has been obtained by 
single-crystal X-ray crystallographic analyses by others.
18,41
 The molecular structures of the zinc 
compounds reported here reveal mononuclear structures for 2-4, 6-8 and binuclear for 9. In all 
compounds, L chelates through both nitrogen atoms.  
 
Scheme 1. The ligands L
n
 (n = 1 – 5) with numbering protocol and their zinc(II) compounds 1 – 9. 
 
Experimental 
General considerations.  
All chemicals were used as purchased without purification: NaN3, pyridine-2-carboxaldehyde 
(Merck), Zn(OAc)2 (Loba-chemie), aniline, ZnCl2 (Sd Fine), ZnBr2, ZnI2 (Sigma-Aldrich), o-
toluidine (Thomas Bakers), p-toluidine, o-anisidine (CDH), p-aminobenzoic acid (Hi-Media). p-
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(carbomethoxyl)aniline (M.p. 113-115 °C) was prepared by reacting a methanol solution of p-
aminobenzoic acid with SOCl2 under ice-cold conditions followed by a suitable work-up 
procedure, as described in ref. 47. The ligands (L
1
-L
5
; Scheme 1) were prepared in situ from 
pyridine-2-carboxaldehyde and the corresponding aniline. Solvents were purified by standard 
procedures and were freshly distilled prior to use. Melting points were recorded in capillary 
tubes on a Scanca apparatus and are uncorrected. Elemental analyses were performed using a 
Perkin Elmer 2400 series II instrument. IR spectra in the range 4000-400 cm
–1 
were obtained 
using KBr pellets on a Perkin Elmer Spectrum BX series FT-IR spectrophotometer. The 
1
H 
NMR spectra were recorded on a Bruker Avance II spectrometer and measured at 400.13 MHz. 
The 
1
H chemical shifts were referenced to Me4Si set at 0.00 ppm. Steady-state absorption spectra 
were recorded at ambient temperature in acetonitrile (spectroscopy grade, Merck) solution on a 
Perkin-Elmer model Lambda25 absorption spectrophotometer. Fluorescence spectra were 
obtained on a Hitachi model FL4500 spectrofluorimeter (with the excitation and emission slits 
fixed at 10 and 20 nm, respectively) and corrected for the instrument response function. Quartz 
cuvettes of 10 mm optical path length received from PerkinElmer, USA (part no. B0831009) and 
Hellma, Germany (type 111-QS) were used for measuring absorption and fluorescence spectra, 
respectively. Fluorescence quantum yields (f) were calculated by comparing the total 
fluorescence intensity over the whole fluorescence spectroscopic range with that of a standard 
using the method described elsewhere.
48,49
 The relative experimental error of the measured f 
was estimated within ±10%. Solution electrical conductivity measurements were made with a 
Wayne Kerr automatic precision bridge 6440B. 
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Synthesis of zinc compounds 
The zinc(II) compounds reported here are numbered as 1-9 (see Scheme 1) for 
convenience of discussion. Details of the procedures have been outlined for the syntheses of 1 
and 9. Compounds 2 – 8 were synthesized by following the procedure described for 1. 
 
Synthesis of [Zn(Cl)2(L
1
)] (1). To a solution of pyridine-2-carboxaldehyde  (0.172 g, 1.60 mmol) 
in  ethanol (5 mL) was added a solution of aniline (0.15 g, 1.61 mmol) in ethanol (5 mL). The 
mixture was stirred at ambient temperature for 30 min. To this reaction mixture, ZnCl2.2H2O 
(0.22 g, 1.61 mmol) in methanol (20 mL) was added drop-wise under stirring conditions, which 
resulted in the immediate formation of a yellow precipitate. The stirring was continued for 3 h 
and then the mixture was filtered. The residue was washed with methanol (3 x 5 mL) and dried 
in vacuo. The dried solid was dissolved by boiling in 50 mL of acetonitrile and filtered while hot. 
The filtrate was left for slow evaporation at room temperature affording yellow crystalline 
material. Yield 0.35 g (64%). M.p. 270-271 °C (M.p. 300 °C (dec.).
18
 Anal. Calc. for 
C12H10Cl2N2Zn: C, 45.23; H, 3.17; N, 8.80. Found: C, 45.30; H, 3.12; N, 8.88%. Ʌm (CH3CN): 4 
-1cm2mol-1. IR (cm–1): 1592 asym(C(H)=N) + (C=N)py; 1498, 1444 (C=N)py. 
1
H-NMR 
(DMSO-d6): 8.93 [d, 1H, H-3
’
], 8.62 [s, 1H, H-7], 8.04 [t, 1H, H-5
’
], 8.02 [d, 1H, H-6
’
], 7.63 [t, 
1H, H-4’], 7.39-7.20 [m, 5H, H-2,3,4,5,6] ppm. The spectroscopic data reported in ref. 18 
correspond well within the experimental errors.  
Compounds 2 – 9 were prepared as yellow crystals in a manner similar to that described 
for the preparation of 1, using appropriate anilines and zinc(II) halides or azides as starting 
materials. 
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Synthesis of [Zn(Br)2(L
1
)] (2). A similar synthetic procedure as for 1 was used except that ZnCl2 
was replaced by ZnBr2, giving pale yellow crystals from acetonitrile solution. Yield 61%. M.p. 
318-320 °C. Anal. Calc. for C12H10Br2N2Zn: C, 35.38; H, 2.47; N, 6.88. Found: C, 35.50; H, 
2.52; N, 6.80%. Ʌm (CH3CN): 5 
-1
cm
2
mol
-1
. IR (cm
–1
): 1592asym(C(H)=N) + (C=N)py; 1498, 
1444 (C=N)py. 1H-NMR (DMSO-d6): 9.03 [d, 1H, H-3’], 8.72 [s, 1H, H-7], 8.15 [t, 1H, H-5’], 
8.04 [d, 1H, H-6’], 7.76 [t, 1H, H-4’], 7.33 [m, 5H, H-2,3,4,5,6] ppm. 
 
Synthesis of [Zn(Cl)2(L
2
)] (3). A similar synthetic procedure as for 1 was used except that aniline 
was replaced by o-toluidine, giving pale yellow crystals from acetonitrile solution. M.p. 269-270 
°C. Anal. Calc. for C13H12Cl2N2Zn: C, 46.95; H, 3.64; N, 8.42. Found: C, 47.10; H, 3.62; N, 
8.50%. Ʌm (CH3CN): 6 
-1
cm
2
mol
-1
. IR (cm
–1
): 1634 asym(C(H)=N); 1597, 1488, 1444 
(C=N)py. 1H-NMR (DMSO-d6): 8.70 [d, 1H, H-3’], 8.50 [s, 1H, H-7], 8.05 [d, 1H, H-6’], 7.97 
[t, 1H, H-5’], 7.51 [t, 1H, H-4’], 7.08 [m, 3H, H-2,3,5], 6.88 [d, 1H, H-4], 3.40 [s, 3H,CH3] ppm. 
 
Synthesis of [Zn(Cl)2(L
3
)] (4). A similar synthetic procedure as for 1 was used except that aniline 
was replaced by p-toluidine, giving pale yellow single crystals from acetonitrile solution. Yield: 
71%. M.p. 340-345 °C. Anal. Calc. for C13H12Cl2N2Zn: C, 46.95; H, 3.64; N, 8.42. Found: C, 
47.10; H, 3.52; N, 8.50%. Ʌm (CH3CN): 6 
-1
cm
2
mol
-1
. IR (cm
–1
): 1626 asym(C(H)=N); 1573, 
1460, 1434 (C=N)py. 1H-NMR (DMSO-d6): 8.91 [d, 1H, H-3’], 8.62 [s, 1H, H-7], 8.04 [t, 1H, 
H-6’], 7.92 [d, 1H, H-5’], 7.65 [t, 1H, H-4’], 7.21 [br m, 2H, H-3,5], 7.07 [d, 2H, H-2,6], 2.25 [s, 
3H, CH3] ppm. The spectroscopic data reported in ref. 20 correspond well within the 
experimental errors although the compound was prepared by following a different method.  
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Synthesis of [Zn(Cl)2(L
4
)] (5). A similar synthetic procedure as for 1 was used except that aniline 
was replaced by p-(carbomethoxyl)aniline giving pale yellow microcrystalline material from 
acetonitrile solution. Yield: 66%. M.p. 259-260 °C. Anal. Calc. for C14H12Cl2N2O2Zn: C, 44.66; 
H, 3.21; N, 7.44. Found: C, 44.50; H, 3.32; N, 7.50%. Ʌm (CH3CN): 10 
-1
cm
2
mol
-1
. IR (cm
–1
): 
1714 asym(C=O); 1592 asym(C(H)=N) + (C=N)py; 1439 (C=N)py. 
1
H-NMR (DMSO-d6): 
9.06 [d, 1H, H-3’], 8.76 [s, 1H, H-7], 8.15 [m, 4H, H-5’,6’], 8.02 [m, 2H, H-3,5], 7.75 [t, 1H, H-
4’],  7.50 [d, 2H, H-2,6], 3.41 [s, 3H, CO2CH3] ppm. 
 
Synthesis of [Zn(Br)2(L
4
)] (6). A similar synthetic procedure as for 1 was used except that ZnCl2 
and aniline were replaced by ZnBr2 and p-(carbomethoxyl)aniline, respectively, giving pale 
yellow single crystals from acetonitrile solution. Yield: 66%. M.p. 262-265 °C. Anal. Calc. for 
C14H12Br2N2O2Zn: C, 36.13; H, 2.60; N, 6.02. Found: C, 35.90; H, 2.44; N, 6.10%. Ʌm 
(CH3CN): 10 
-1
cm
2
mol
-1
. IR (cm
–1
):1721 asym(C=O); 1591 asym(C(H)=N) + (C=N)py; 1479, 
1445 (C=N)py. 1H-NMR (DMSO-d6): 9.07 [d, 1H, H-3’], 8.80 [s, 1H, H-7], 8.14 [m, 4H, H-
5’,6’], 7.99 [m, 2H, H-3,5], 7.79 [t, 1H, H-4’], 7.44 [d, 2H, H-2,6], 3.46 [s, 3H, CO2CH3] ppm. 
 
Synthesis of [Zn(I)2(L
4
)] (7). A similar synthetic procedure as for 1 was used except that ZnCl2 
and aniline were replaced by ZnI2 and p-(carbomethoxyl)aniline, respectively, giving pale yellow 
single crystals from acetonitrile solution. Yield: 51%. M.p. 270-271
°
C. Anal. Calc. for 
C14H12I2N2O2Zn: C, 30.06; H, 2.16; N, 5.01. Found: C, 30.40; H, 2.10; N, 5.50%. Ʌm (CH3CN): 
4 -1cm2mol-1. IR (cm–1): 1715 asym(C=O); 1588 asym(C(H)=N) + (C=N)py; 1476, 1432 
(C=N)py. 1H-NMR (DMSO-d6): 9.06 [d, 1H, H-3’], 8.87 [s, 1H, H-7], 8.19 [m, 2H, H-5’,6’], 
8.00 [d, 2H, H-3,5], 7.84 [t, 1H, H-4’], 7.43 [d, 2H, H-2,6], 3.91 [s, 3H, CO2CH3] ppm. Note: 
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Results of elemental analysis could not be improved further, yet the purity of the sample was 
judged on the basis 
1
H NMR results.  
 
Synthesis of [Zn(Cl)2(L
5
)] (8). A similar synthetic procedure as for 1 was used except that aniline 
was replaced by o-anisidine giving pale yellow single crystals from acetonitrile solution. Yield: 
59%. M.p. 282-284 °C. Anal. Calc. for C13H12Cl2N2OZn: C, 44.80; H, 3.47; N, 8.04. Found: C, 
44.70; H, 3.62; N, 8.10%. Ʌm (CH3CN): 5 
-1
cm
2
mol
-1
. IR (cm
–1
): 1593 asym(C(H)=N) + 
(C=N)py; 1499, 1470 (C=N)py. 1H-NMR (DMSO-d6): 9.25 [s, 1H, H-7], 8.71 [d, 1H, H-3’], 
8.10 [m, 2H, H-5’,6’], 7.72 [m, 2H, H-4,4’], 7.38 [t, 1H, H-6], 7.05 [m, 2H, 3,5], 4.00 [s, 
3H,OCH3] ppm. 
 
Synthesis of [Zn(-N3)(N3)(L
3
)]2 (9). To a solution of pyridine-2-carboxaldehyde  (0.15 g,1.40 
mmol) in  ethanol (5 mL) was added a solution of p-toluidine (0.15 g, 1.40 mmol) in ethanol (10 
mL). The mixture was stirred at ambient temperature for 30 min and was added drop-wise to a 
stirred methanolic solution containing Zn(N3)2 (prepared in situ from the reaction of Zn(OAc)2 
(0.31 g, 1.40 mmol) in 20 mL methanol with an excess of NaN3 (0.18 g, 2.74 mmol) in 30 mL 
methanol), which resulted in the immediate formation of a yellow precipitate. The stirring was 
continued for 3 h and then the mixture was filtered. The residue was washed thoroughly with 
water, then with methanol (3 x 5 mL) and dried in vacuo. The dried solid was dissolved by 
boiling in 60 mL of acetonitrile and filtered while hot. The filtrate, upon cooling to room 
temperature, afforded yellow crystalline material. Yield 0.29 g (47%). M.p. 222-225 °C. Anal. 
Calc. for C26H24N16Zn2: C, 45.17; H, 3.50; N, 32.42. Found: C, 45.30; H, 3.10; N, 32.66%. Ʌm 
(CH3CN): 9 
-1
cm
2
mol
-1
. 1630 asym(C(H)=N); 1591; 1475, 1441 (C=N)py; 2039 as(N3). 
1
H-
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NMR (DMSO-d6): 8.82 [d, 1H, H-3’], 8.70 [s, 1H, H-7], 8.09 [m, 2H, H-5’,6’], 7.65 [t, 1H, H-
4’], 7.23 [d, 2H, H-3,5], 7.18 [d, 2H, H-2,6], 2.35 [s, 3H, CH3] ppm. Note: While no incident 
occurred while using azide during preparation and isolation, care in handling azides must be 
exercised owing to their potentially explosive nature. 
 
X-ray crystallography 
Crystals of zinc compounds (2-4, 6-9) suitable for an X-ray crystal-structure determination were 
obtained by slow evaporation of acetonitrile solutions of the respective compounds at room 
temperature. The data for 2, 4, 6, 7 and 9 were recorded at low temperature on an Agilent 
Technologies SuperNova area-detector diffractometer
50
 using Mo K radiation ( = 0.71073 Å) 
from a micro-focus X-ray source and an Oxford Instruments Cryojet XL cooler. The 
measurements for 3 and 8 were made at low temperature on a Nonius KappaCCD 
diffractometer
51 
with graphite-monochromated Mo K radiation ( = 0.71073 Å) and an Oxford 
Cryosystems Cryostream 700 cooler. 
 Data reduction on 3 and 8 were performed with HKL Denzo and Scalepack
52 
while 
CrysAlisPro
50
 was used for 2, 4, 6, 7 and 9. The intensities were corrected for Lorentz and 
polarization effects. Empirical absorption corrections based on the multi-scan method using 
spherical harmonics
53
 were applied. Equivalent reflections were merged. The data collection and 
refinement parameters are given in Table 1, and perspective views of the structures are shown in 
Figs. 2-4. The structures were solved by direct methods using SHELXS97
54
 which revealed the 
positions of all non-hydrogen atoms. The largest peak of residual electron density in 2 is within 
0.90 Å of the Zn-atom. In 9, the molecule is a dinuclear Zn-complex with a crystallographic 
centre of inversion located in the middle of the central Zn2N2 core. The non-hydrogen atoms in 
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each structure were refined anisotropically. All of the H-atoms were placed in geometrically 
calculated positions and refined by using a riding model where each H-atom was assigned a 
fixed isotropic displacement parameter with a value equal to 1.2Ueq of its parent atom (1.5Ueq for 
any methyl group). The refinement of each structure was carried out on F
2
 by using full-matrix 
least-squares procedures, which minimized the function w(Fo2–Fc2)2. A correction for 
secondary extinction was applied for 3 and 6-8. Two reflections in 8, whose intensities were 
considered to be extreme outliers, were omitted from the final refinement. The SHELXL97 
program
54
 was used for all refinements. 
 
Isolation of peripheral blood mononuclear cells (PBMC) from human blood  
PBMC were separated from fresh peripheral human blood of normal healthy donors by the ficoll-
paque (Histopaque-1077) density gradient centrifugation method. The oxalated blood was 
immediately diluted with sterile 1:1 phosphate buffer saline (PBS), layered over ficoll paque 
(1.077 density) and centrifuged at 400 xg for 30 minutes at room temperature. The PBMC layer 
formed above the ficoll level was removed by aspiration and suspended in PBS, centrifuged and 
the pellet suspended in RPMI medium for culture. The viability of the cells was checked with the 
trypan blue exclusion test: the viable cells exclude the dye and the non-viable cells take-up the 
dye giving a blue coloration. The diluted cell suspension was taken in 0.2% trypan blue dye in 
saline and dye positive and negative cells were counted separately under a microscope using 
Hemocytometer, and the amount expressed in percentage. The cells were found to be 98% viable 
by the trypan blue dye exclusion test. 
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Experimental protocols for MTT, LDH and DNA binding assays  
The drug-induced cytotoxicity was measured by the MTT assay.
55
 Briefly, 50,000 HeLa cells per 
well (24 well plate) or 5000 PBMC per well (96 well plate) were incubated in the presence or 
absence of the indicated test samples (zinc compounds: 1, 3-5 and 8) and cisplatin in a final 
volume of 1 mL for 72 h at 37 °C in duplicate. Then, 0.025 mL of MTT solution (5 mg/mL in 
Phosphate buffered saline (PBS)) was added to each well. After 2 h of incubation at 37 
°
C, 0.5 
mL of extraction buffer (20% sodium dodecyl sulfate (SDS) in 50% dimethlylformamide) was 
added. After an overnight incubation at 37 
°
C, the absorbance at 570 nm was measured using a 
96 well multiscanner auto reader (Coda, Bio Rad) with the extraction buffer as blank. Mean 
absorbance was taken and cell death was calculated considering untreated cells viability as 
100%. 
The cytosolic marker lactate dehydrogenase (LDH) enzyme was assayed from the culture 
supernatant
56
 from zinc compounds-treated cells. Cells were treated with different concentrations 
of zinc compounds 1, 3-5 and 8 for 72 h, and the culture supernatants were collected and 
incubated with substrate solution (0.23 M sodium pyruvate and 5 mM NADH in 0.1 M 
phosphate buffer, pH 7.5). The absorbance was recorded at 420 nm after 30 min of incubation at 
37 °C.    
In vitro DNA binding assays were performed with HeLa cells which were cultured in 60 
mm petri dishes overnight and stimulated with 1 nM of tumour necrosis factor (TNF) for 1 h. 
The nuclear extracts (NE) were prepared and 15 µg of NE proteins were taken for in vitro DNA 
binding assay.
57
 NE were incubated with different concentrations (see above) of zinc compounds 
1, 3-5 and 8, for 30 min at 37
 
°C and then transcription factors NF-κB and AP-1, and p53 DNA 
binding were assayed using 
32
P-labelled specific gel shift double stranded oligonucleotides at 6% 
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native PAGE. The gels were dried, exposed to Phosphorimager screen overnight, scanned and 
analysed in Phosphorimager (Fuji, Japan). 
Gel shift oligonucleotides: 
NF-κB: 5’-TTG TTA CAA GGG ACT TTC CGC TGG GGA CTT TCC AGG GAG GCG TGG-
3’ 
AP-1: 5'-CGC TTG ATG ACT CAG CCG GAA-3' 
p53: 5'-TAC AGA ACA TGT CTA AGC ATG CTG GGG ACT-3' 
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Table 1 Crystal data and refinement details
a
 for zinc compounds 2-4, 6-9 
 
 
 
 
 
 
 2 3 4 
Empirical formula C12H10Br2N2Zn C13H12Cl2N2Zn C13H12Cl2N2Zn 
Formula weight 407.41 332.54 332.51 
Crystal size (mm) 0.05  0.17  0.20 0.12  0.20  0.28 0.14  0.15  0.25  
Crystal morphology Tablet Prism Prism 
Temperature (K) 160(1) 160(1)  160(1)  
Crystal system Triclinic Monoclinic Monoclinic 
Space group P
_
1 P21/c   P21/n   
a (Å) 7.8621(3)  13.8601(2)  11.7947(3)  
b (Å) 8.8368(3) 8.2826(1) 9.78427(18) 
c (Å) 10.0742(3)  12.6858(2)  12.0762(2)  
 (°) 102.598(3) 90 90 
 (°) 100.816(3) 105.682(1) 104.121(2) 
 (°) 96.996(3) 90 90 
V (Å
3
) 661.19(4)  1402.09(4)  1351.51(5)  
Z 2 4 4 
Dx (g cm
–3
) 2.046 1.575 1.634 
 (mm–1) 7.897 2.115 2.194 
Transmission factors (min, 
max) 
0.534, 1.000 0.641, 0.773  0.862, 1.000  
 range (°) 2.12 – 29.42 2.89 – 30.03 2.71–30.37 
Reflections measured 14700 40741 17244 
Independent reflections; Rint 3307; 0.041 4100;  0.045  3766; 0.023 
Reflections with I > 2(I) 2810 3463 3340 
Number of parameters 154 165 164 
R(F)
 b
 [I > 2(I)reflns] 0.0346 0.0318 0.0275 
wR(F
2
) 
c
 (all data) 0.0777 0.0824 0.0725 
GOF(F
2
) 1.039 1.031 1.134 
max, min (e, Å
–3
) 2.86, -1.05  1.13, -0.50  0.65, -0.30  D
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Table 1 contd. 
6 7 8 9 
C14H12Br2N2O2Zn  C14H12I2N2O2Zn C13H12Cl2N2OZn C26H24N16Zn2 
465.45 559.45 348.54 691.34 
0.18  0.20  0.25 0.10  0.18  0.22 0.10  0.15  0.43 0.10  0.12  0.22 
Prism Prism Tablet Prism 
160(1) 160(1) 160(1) 160(1) 
Monoclinic Monoclinic  Monoclinic Monoclinic 
C2/c   C2/c   P21/n   P21/c   
17.6449(3) 18.3886(2) 7.6346(1) 8.69797(13)  
13.1494(2) 13.12663(16) 18.9972(4) 17.7362(3)  
13.8486(2) 14.11370(17)  9.7619(1)  9.75808(16) 
90 90 90 90 
99.4538(15) 100.1521(12) 94.8419(12)  107.3946(17)  
90 90 90 90  
3169.51(9)  3353.44(7) 1410.77(4)   1436.53(4) 
8 8 4 2 
1.951 2.216 1.641 1.598  
6.612 5.153 2.111 1.720 
0.591, 1.000 0.620, 1.000 0.627, 0.816 0.885, 1.000 
2.33–29.54 2.25– 32.37 2.14 – 30.02 2.30 – 30.27  
18117 26438 33068 18231  
4048; 0.037 5627; 0.026 4118; 0.048 3948; 0.023 
3542 5061 3469 3516 
192 192 174 200 
0.0264 0.0192 0.0287 0.0246 
0.0570 0.0439 0.0720 0.0598 
1.039 1.053 1.054 1.079 
0.58, -0.66 0.75, -0.60 0.54, -0.64  0.33, -0.33  
a
Data for 1 has been reported in refs. 18 and 41.  
b 
R1 = ||Fo| – |Fc||/|Fo|.  
c 
wR2 = [[w(Fo
2
 – Fc
2
)
2
]/ [w(Fo
2
)
2
]]
1/2
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Results and discussion 
Syntheses  
Zinc compounds 1-9 were prepared by one-pot reaction of ZnX2 (X = halides or azide) with L
n
 
(generated in situ from pyridine-2-carboxaldehyde and a substituted aniline), akin to that 
reported for mercury analogues.
48,49
 The general stoichiometries of the [Zn(X)2(L
n
)] complexes 
have been corroborated by the microanalytical results, which clearly evidence the formation of 
1:1 adducts between the bidentate N-donors L
n
 and ZnX2. In all cases, air stable pale yellow 
solids were obtained in moderate to good yields and these compounds behave as non-electrolytes 
in acetonitrile solution. Compounds 1-9 are soluble in water, alcohol, acetonitile, DMSO and 
DMF. The spectroscopic properties were studied using UV-Visible, fluorescence, IR and 
1
H 
NMR spectroscopy while the solid state structures of 2-4 and 6-9 were determined by single 
crystal X-ray crystallography. 
 
IR, NMR, UV-Vis and fluorescence spectroscopy 
The IR spectra of 1-9 exhibit moderately intense bands in the 1590-1620 cm
-1
 range which were 
assigned to the asym(C(H)=N) stretch of the coordinated Schiff base ligands.
48,49,58
 In addition, 
well resolved-sharp bands of variable intensity observed in the 1600-1580, 1490-1475 and 1450-
1435 cm
-1
 regions were assigned to the coordinated pyridine ring.
48,49,58-60
 In 9, it is worth 
mentioning that the very strong band at 2037 cm
-1
 corresponds to as(N3),
61,62
 a value similar to 
that recently reported for {[Hg(N3)2L]2}n.
48
 The 
1
H NMR spectra of the compounds in DMSO-d6 
solution displayed the expected signals, which correlate well with the hydrogen atoms present in 
the molecules. Coupling constants could not be determined with certainty owing to the broad 
unresolved nature of the signals.
48,49
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Table 2 Photophysical data for compounds 1-9 in acetonitrile solution 
 
Compounds 
Electronic spectroscopic data  
max (nm);M
-1
cm
-1 
Photoluminescence data  
em (nm)
a
              F  
1 328 (13,191)  412, 430  0.34 
2 329 (26,190)  411, 431 0.06 
3 334 (21,329)  414, 430     0.16 
4 342 (14,260)  413, 430     0.19 
5 328(14,150)        411, 432     0.09 
6 327 (12,228)  414, 427     0.04 
7 325(26,682)  412, 429     0.11 
8 325(10,174), 371(11,308) 413, 431, 502       0.13 
9 340(11,720)  410, 426 0.08 
a
The long wavelength emission appears as a shoulder in all the cases. 
 
 
Table 2 summarizes the solution UV-Vis and fluorescence properties of compounds 1-9. The 
absorption spectra of all compounds were recorded in the 300-450 nm range in acetonitrile 
solutions at concentrations of ~10
-5
 M; they generally comprise one intense band, except for 8 
where two overlapping bands were detected (Fig. 1a). The electronic spectra of the ligands are 
not available. In general, the zinc compounds displayed a broad fluorescent emission band at λem 
= 410 nm (Fig. 1b) along with a shoulder in the range ~426-432 nm at room temperature. The o-
methoxy derivative 8 displayed an additional band at 502 nm. These emissions could not be 
assigned as metal-to-ligand charge transfer (MLCT) or ligand-to-metal charge transfer (LMCT) 
as the zinc(II) ion, with a d
10
 configuration, is not easily oxidized or reduced.
63
 The emissions are 
attributed to the intraligand (IL) (π–π*) fluorescent emission. On the whole, the Zn compounds 
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show a very low fluorescent quantum yields (Table 2), indicating that they are weak emitters at 
room temperature.  
 
Fig. 1 (a) UV–Vis spectra of compounds 1-9 in acetonitrile (concentration ~10-5 M) (b) 
Fluorescence spectra of compounds 1-9 in acetonitrile (concentration ~10
-5
 M) obtained by 
excitation at the respective absorption maxima. 
 
Molecular structures 
Although a substantial amount of work has been reported with analogous L ligands (see  
Introduction), to our knowledge the extant literature contains no crystallographic characterization 
of L except for the one described by Wiebcke et al. and that too suffers from whole molecule 
disorder.
64
 In view of this and to assign the diagnostically important experimental infrared bands, 
quantum chemical calculations were carried out on some of these ligands and their structural 
parameters were reported earlier by us.
48
 The crystal structure of compound 1 has been reported 
by others on two different occasions.
18,41
 Recently, the structure of 1 has also been validated by 
ground state optimization by various DFT methods.
65 
The results of the crystal structure 
determinations of zinc compounds 2-4 and 6-9, now reported, are consistent with the chemical 
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and spectroscopic analyses. The molecular structures of 2-4, 6 and 7 are displayed in Fig. 2 and 
those of 8 and 9 in Fig. 3 and Fig. 4, respectively.  Generally, the zinc atom prefers a tetrahedral 
environment; however, depending on the bulkiness of the ligands, coordination numbers between 
two and six can be realized. In 2-4, 6 and 7, the Zn cations are in a tetrahedral coordination 
environment, with 4 values
66
 in the range 0.83 – 0.89 (Table 3). However in 8, the Zn cation is 
in a distorted square pyramidal environment (5 = 0.19)
67 
with the basal plane defined by atoms 
Cl2, O1, N1 and N2 and the apical position occupied by atom Cl1. The molecule of [Zn(-
N3)(N3)(L
3
)]2 (9) is binuclear and sits across a crystallographic centre of inversion. The 
coordination sphere of the symmetry-unique zinc atom is trigonal bipyramidal (5 = 0.67)
67
 with 
atoms N1, N3 and N6 in the equatorial positions and the axial sites occupied by atoms N2 and 
N6
i
 (Fig. 4). In all the compounds, both imino-N and pyridine-N atoms are involved in the 
chelation, leading to the formation of at least one metallacycle five-membered ring. In addition, a 
second five-membered metallacycle is found in 8 owing to the coordination of the methoxy O-
atom to zinc (Fig. 3), while in 9, a four-membered ring is present in the central Zn2N2 core (Fig. 
4).  
As a result of imposed steric constraints, either from a non-chelating ortho- methyl 
substituent on the phenyl ring (as in 3) or from packing interactions (as in 6 and 7), the organic 
ligands in some complexes deviate significantly from a planar conformation. This is reflected in 
the Zn1N2C7C12 torsion angles (absolute values range from 6.6(3) to 69.4(2)º; Table 3) and 
also in the dihedral angles between the planes of the phenyl and Zn-N-C-C-N metallacyclic rings 
which adopt values from 7.20(16)° (in 2) to 64.11º (in 3). The organic chelating groups in 2, 4 
and 8 are the most planar with the Zn1N2C7C12 torsion angles and the corresponding 
dihedral angles all being less than 10° (Table 3). In compound 9, these two parameters adopt 
D
al
to
n
 
Tr
an
sa
ct
io
n
s 
A
cc
ep
te
d 
M
an
u
sc
rip
t
Pu
bl
ish
ed
 o
n 
11
 O
ct
ob
er
 2
01
3.
 D
ow
nl
oa
de
d 
by
 N
or
th
 E
as
te
rn
 H
ill
 U
ni
ve
rs
ity
 o
n 
22
/1
0/
20
13
 0
9:
08
:3
7.
 
View Article Online
DOI: 10.1039/C3DT52062E
21 
 
intermediate values, while compound 3 is the most twisted case on account of the ortho- methyl 
substituent. In all the compounds, the N1–C6 bond distances are in the range 1.275(4) – 1.284(2) 
Å, which confirms the double-bond character of the methylidene groups. In general, the metal-
Npyridine (Zn1N1) bond distances are shorter than the metal-Nmethylidene (Zn1N2) lengths (Table 
3), the exception arising only in 8 probably as a result of a certain amount of trans effect from 
the coordinated methoxide group (O1Zn1N1 = 146.07(5)º). In 9, the terminal Zn-Nazide bond 
lengths (1.9799(13) Å) are significantly shorter than those involving the asymmetrically bridging 
azide (2.0414(12), 2.1918(12) Å) and the two zinc atoms of the central Zn2N2 unit are 3.2517(2) 
Å apart. 
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Fig. 2 Perspective views of the molecular structures of [Zn(Br)2(L
1
)] (2), [Zn(Cl)2(L
2
)] (3), 
[Zn(Cl)2(L
3
)] (4), [Zn(Br)2(L
4
)] (6) and [Zn(I)2(L
4
)] (7) with the atomic numbering schemes. 
Displacement ellipsoids are drawn at the 30% probability level and H atoms are shown as small 
spheres of arbitrary radii. 
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Table 3 Zn coordination geometry and selected geometrical parameters for the zinc compounds 2-4 and 
6-9 
 
 2 3 4 6 7
 
8 9 
Geometry
a
 
Tet Tet Tet Tet Tet Spy Tbp 
 
Coordination sphere  
N2Br2 N2Cl2 N2Cl2 N2Br2 N2I2 N2Cl2O N5 
 
Geometry indices, 4 (5) 0.88 0.83 0.89 0.89 0.88 (0.19) (0.67) 
 
        
Zn1–N1 (Å) 2.063(3) 2.0608(15) 2.0558(16) 2.0475(17) 2.0454(14) 2.1313(15) 2.0735(11) 
 
Zn1–N2 (Å) 
 
2.086(3) 
 
2.0755(15) 
 
2.0782(15) 2.0960(17) 2.0992(14) 
 
2.1042(13) 2.1945(12) 
 
N2–C6 (Å)      1.275(4) 1.277(2) 1.284(2) 1.282(3) 1.283(2) 1.280(2) 1.2759(18) 
 
        
N1–Zn1–N2 (°) 80.81(11) 80.59(6) 81.17(6) 80.71(7) 80.52(5) 77.82(5) 77.62(4) 
 
Zn1–N2–C7–C12 (°)  6.6(4) -69.4(2) 8.0(2) 27.4 (3) 27.8(2) 9.35(19) 14.13(18) 
 
Metallacycle/phenyl plane 
dihedral angle (°) 
7.20(16) 64.11(10) 8.71(9) 26.28(10) 27.01(7) 7.23(8) 17.43(7) 
Shortest ZnZn (Å) 6.2723(7) 5.6040(3) 6.4256(3) 5.5039 (3) 5.7174(3) 5.3058(3) 7.6437(3) 
 
a
 Tet = Tetrahedral; Spy = Square pyramidal and Tbp = Trigonal bipyramidal. 
 
 
 
 
 
 
D
al
to
n
 
Tr
an
sa
ct
io
n
s 
A
cc
ep
te
d 
M
an
u
sc
rip
t
Pu
bl
ish
ed
 o
n 
11
 O
ct
ob
er
 2
01
3.
 D
ow
nl
oa
de
d 
by
 N
or
th
 E
as
te
rn
 H
ill
 U
ni
ve
rs
ity
 o
n 
22
/1
0/
20
13
 0
9:
08
:3
7.
 
View Article Online
DOI: 10.1039/C3DT52062E
24 
 
 
Fig. 3 Perspective view of the molecular structure of [Zn(Cl)2(L
5
)] (8) with the atomic 
numbering scheme. Displacement ellipsoids are drawn at the 30% probability level and H atoms 
are shown as small spheres of arbitrary radii. 
 
 
Fig. 4 Perspective view of the two centrosymmetrically-related azide-bridged units, found in the 
crystal structure of [Zn(-N3)(N3)(L
3
)]2 (9) with the atomic numbering scheme. Displacement 
ellipsoids are drawn at the 30% probability level and H atoms are shown as small spheres of 
arbitrary radii. 
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Non-covalent non-classical intermolecular interactions are present in all the compounds, 
particularly in the case of compounds 6 and 7, where the ester moieties act as medium-strong 
acceptors of CphenylH···O interactions [d(D∙∙∙A) in the range 2.973(3) – 3.062(2) Å and 
(DH∙∙∙A) between 113 and 118º] giving rise to infinite one-dimensional chains running 
parallel to the crystallographic b axis (Fig. S1 and S2). In the other compounds, such interactions 
involve the halogen atoms (or the terminal nitrogen atom of the non-bridging azide in 9) as the 
CphenylH acceptors [d(D∙∙∙A) distances longer than 3.315(3)Å]. In this respect, complex 3 is a 
good example (Fig. S2): every molecule is surrounded, only by means of such contacts, by eight 
other molecules and in this cluster the shortest ZnZn distance is 5.6040(3) Å. 
Intermolecular ∙∙∙ stacking interactions have been found in these structures, with some 
of their values suggesting a perfect (face-to-face), or slightly offset stack ring centroid∙∙∙centroid 
distances values typically fall in the range of 3.3 – 3.8 Å.68 Indeed, the one-dimensional chains in 
6 are assembled by such interactions which involve the phenyl rings of adjacent molecules 
(centroid∙∙∙centroid = 3.6782(13) Å, Fig. S1, top); in 7 such contacts are weaker (3.8871(10) Å, 
Fig. S1, bottom). The shortest centroid∙∙∙centroid contacts of 3.5175(9) and 3.6523(11) Å were 
found for, respectively, the intermolecular interactions involving the pyridine rings of adjacent 
molecules in 9 (Fig. S3) and the phenyl ring in one molecule and the pyridine moiety in a vicinal 
molecule in 4 (Fig. S4). Such interactions assemble these structures into chains which run 
parallel to the crystallographic c axis in 9 or in a zig-zag fashion along the b axis in 4. The 
minimum ZnZn distances in 9 and 4 are 7.6437(3) and 6.4256(3) Å, respectively. In 2, 
3.674(2) Å is the centroid∙∙∙centroid distance for the shortest intermolecular ∙∙∙ interaction, 
which involves the metallacycle and the phenyl ring of one molecule interacting with the phenyl 
ring and the metallacycle, respectively, of an adjacent molecule (Fig. S5). By means of such 
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interactions, the molecules of 2 appear to be associated in pairs, which then interact with 
neighbouring pairs through pyridine∙∙∙phenyl ∙∙∙ contacts of 3.872(2) Å, resulting in stacks of 
molecules arranged parallel to the crystallographic a axis. The ZnZn distance within these pairs 
of molecules (7.4792(7) Å) is considerably greater than the ZnZn distance between pairs in the 
same stack (6.2723(7) Å, Table 3). Also in 4 and in 8 there are ∙∙∙ interactions linking the 
metallacyclic rings, yet of weaker intensity (centroid∙∙∙centroid distances in the range 3.8035(10) 
– 3.9501(8) Å); together with 2, these compounds present the flattest L ligands found in this 
study (Table 3). 
 
 
Biological evaluation 
To elucidate the mechanism of cytotoxic potency, we have selected the five dichlorozinc 
derivatives 1, 3-5 and 8, see Scheme 1, whose molecules satisfy the restrictive terms of 
Lipinski’s rules (low molecular weight (MW ≤ 450); relatively lipophilic (clogP, calculated 
logarithm of the octanol/water partition coefficient, ≤5); hydrogen-bond donor atoms (HBD ≤ 5); 
hydrogen-bond acceptor atoms (HBA ≤ 10); small polar surface area (PSA ≤ 90 Å2)), criteria 
essential for the rational structure-based drug design.
69,70
 The molecules of 1, 3-5 and 8 are small 
(MW ≤ 377) and their solubility in water ultimately makes them biocompatible, which is likely 
to facilitate their biological application, and has prompted us to engineer these compounds as 
potential anticancer agents. Following rational structure-based design principles, the cytotoxicity 
activities of 1, 3-5 and 8 have been investigated in vitro toward the human epithelial cervical 
carcinoma (HeLa) cell lines and the apoptosis-inducing activities were assessed by MTT, LDH 
and DNA binding assays.  
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MTT, LDH and DNA binding assays  
HeLa cells were incubated with different concentrations of the zinc compounds and cisplatin and 
the cell viabilities were assayed by the MTT method. The zinc compounds increased the cell 
death in a concentration-dependent manner (Fig. 5). The IC50 values of the test compounds and 
cisplatin were calculated from the data obtained from MTT assays and are collected in Table 4. 
The cytotoxic effect of cisplatin was considered as the positive control for this experiment. 
 
 
 
Fig. 5 Effect of zinc compounds on cell viability. HeLa cells (50,000/well of 24-well plate) were 
treated with different concentrations of zinc compounds 1, 3, 4, 5 and 8 for 72 h in duplicate. For 
positive control, cisplatin was used for the same assay. Cells were used for MTT assays. The 
plate was kept overnight at 37 
°
C and the absorbance was recorded at 570 nm. The cell death was 
calculated from duplicate samples and indicated as inhibition of cell viability in percentage 
D
al
to
n
 
Tr
an
sa
ct
io
n
s 
A
cc
ep
te
d 
M
an
u
sc
rip
t
Pu
bl
ish
ed
 o
n 
11
 O
ct
ob
er
 2
01
3.
 D
ow
nl
oa
de
d 
by
 N
or
th
 E
as
te
rn
 H
ill
 U
ni
ve
rs
ity
 o
n 
22
/1
0/
20
13
 0
9:
08
:3
7.
 
View Article Online
DOI: 10.1039/C3DT52062E
28 
 
considering untreated cells as 100% viable cells. The experiment was repeated twice and the data 
from one experiment is represented.  
 
Table 4 In vitro IC50 values (μM)
a
 of test zinc compounds 1, 3-5 and 8 and the 
standard drug (cisplatin = CDDP) in HeLa cell line 
 
 
 
 
 
 
 
 
a
 The values are calculated from the data obtained by MTT assay, as shown in Fig. 5. The 
standard drug reference value is cited under identical conditions. The standard 
deviation (in brackets) is calculated from the data obtained from two independent 
experiments. 
 
The molecules of zinc compounds 1, 3-5 and 8 are small (MW ≤ 377) and generally 
small molecules are known to exert several side effects including cytolysis and hence the LDH 
assay was performed. HeLa cells and blood-derived PBMC were incubated with different 
concentrations of zinc compounds 1, 3-5 and 8 for 72 h and the culture supernatant was used in 
the measurement of LDH. No significant increase in the activity of LDH was observed for the 
cells treated with zinc compounds even up to 100 µM concentration for 72 h (Figs. S6 and S7). 
The primary cells (PBMC) treated with the zinc compounds did not show any significant cell 
death and cytolysis, as determined by the MTT and LDH assays, respectively. 
Test compounds/ Standard drug IC50 (μM) 
[Zn(Cl)2(L
1
)] (1) 19.5   (± 0.5) 
[Zn(Cl)2(L
2
)] (3) 28.25 (± 1.25) 
[Zn(Cl)2(L
3
)] (4) 17.75 (± 0.25) 
[Zn(Cl)2(L
4
)] (5) 33.6   (± 1.1) 
[Zn(Cl)2(L
5
)] (8) 20.82 (± 2.32) 
CDDP   0.36 
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In vitro DNA binding assay of zinc compounds 1, 3-5 and 8 was performed with HeLa 
cells. The binding of nuclear transcription factor kappaB (NF-κB), activator protein 1 (AP-1), 
and p53 DNA were determined. Nuclear extracts were incubated with different concentrations of 
zinc compounds and DNA binding was assayed using specific double stranded oligonucleotides. 
The DNA binding was found to decrease with increasing concentration of zinc compounds 1, 3-5 
and 8 for NF-κB, AP-1 and p53 (Fig. 6). The data suggest that the zinc compounds interfere with 
DNA-protein binding, but only for the two higher concentrations (15 and 30 µM).  
 
Fig. 6 The effect of zinc compounds 1, 3-5 and 8 on DNA binding activity. HeLa cells were used to 
isolate the nuclear extracts. The nuclear extracts (15 μg protein) were incubated with different 
concentrations of zinc compounds for 30 min at 37 °C and then the DNA binding activity for NF-κB, AP-
1 and p53 was determined by gel shift assay. 
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Live cells show oxidative burst response that signifies their viability as these cells utilize oxygen 
for biological reactions that need energy for survival. Tetrazolium dye (MTT) converted to 
formazan granules upon exposure to reactive oxygen, and their formation was measured a as 
marker for cell viability. Treatment of HeLa cells with the zinc compounds 1, 3-5 and 8 shows 
moderate cell death indicating potent anti-tumour activity. Although these compounds increase 
cell death, cytolysis was not observed even at higher concentrations, indicating the safe use of 
these compounds for therapy.  
Whether these zinc compounds are specific to tumour or primary cells needs to be studied 
further. As the structural conformity of these zinc compounds might have the ability to bind with 
DNA and inhibit transcription, we have tested the DNA binding of several transcription factors 
in presence of zinc compounds in vitro.  
Indeed, all the zinc compounds have the ability to interfere with DNA-protein binding, as 
shown by NF-κB, p53 and AP-1 DNA binding with their respective consensus promoter binding 
site. This indicates that the zinc compounds in the present investigation are able to inhibit 
transcription binding ability and thus might block the expression of key proteins which are 
involved in cell division. This suggests that these compounds are potentially novel tumour 
therapeutic drugs. Further, toxicity tests on PBMC indicate no significant deleterious effect, 
confirming that the investigated zinc compounds may have therapeutic applications. 
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Conclusions 
The syntheses of nine new neutral small molecules of zinc with (E)-N-(pyridin-2-
ylmethylene)arylamine were successfully accomplished. These compounds have been 
characterized by single crystal X-ray diffraction analysis and spectroscopic methods. The Zn(II) 
compounds displayed distorted tetrahedral (2-4, 6 and 7), square pyramidal (8) or trigonal 
bipyramidal (9) coordination geometries; in the last case, a dinuclear Zn(II) complex was 
obtained. Five water soluble dichlorozinc compounds (1, 3-5 and 8) have been selected on the 
basis of a rational structure-based design approach which may have the ability to target and 
modulate tumour activities. The investigated zinc compounds exhibited in vitro tumour-
inhibiting activities against the HeLa cell line that are much lower than that of cisplatin. 
However, cisplatin has enormous side-effects as an anti-cancer drug, while the higher 
concentrations of zinc compounds did not show any cytolysis, suggesting that they may exert 
less side-effects. Nevertheless, the bioavailability and degradation of these compounds in the 
biological system need to be determined before their use as therapeutics. The investigated Zn(II) 
compounds showed the ability to bind proteins, which is the requisite for a drug to act as an 
anticancer agent. The zinc complexes also exhibited significant cytotoxic activity toward the 
HeLa cell line and their high IC50 values did not induce any cytolysis effect. Binding studies 
indicated that the cell death induced by compound 4 may be caused by an apoptotic pathway 
through inhibition of binding of key transcription factors like NF-κB and AP-1 which are 
responsible for cell proliferation. Although the zinc compounds potently inhibited the p53 DNA 
binding, the tumour suppression may not be that important in the tumour biology since a lot of 
tumour cells have the non-functional p53. The studied zinc compounds predominantly inhibited 
the cell proliferative effect that occurs via inhibition of rate-limiting transcription factors, like 
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NF-κB and AP-1. Further studies are needed to understand the mechanism of action and the 
structure – cellular activity of this class of water soluble zinc compounds.  
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